Aurobindo Pharma Limited has informed the Exchange about acquisition of the branded non-oncology prescription formulations business of Khandelwal Laboratories Private Limited as a going concern, including without limitation inventory, intellectual property, employees, contracts etc. on a slump sale basis is being acquired by Auro Pharma Limited, a wholly owned subsidiary of the Company.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma's wholly owned subsidiary, Auro Pharma Limited, has acquired the branded non-oncology prescription formulations business of Khandelwal Laboratories Private Limited on a slump sale (going concern) basis. The business includes 23 brands across 67 SKUs, 9 pipeline products, around 470 field staff and over 1,600 stockists, focused on anti-infective and pain management therapies. It generated turnover of INR 1,135.3 million and EBITDA of INR 289.9 million in FY2024-25, and has been operational since 1973-74. The deal was signed and closed on January 1, 2026, for a cash consideration of INR 3,250 million, with no regulatory approvals required and no related party involvement.
The acquisition strengthens Aurobindo Pharma's domestic branded formulations portfolio in pain management and anti-infectives, adding scale to its India business. While the INR 325 crore deal size is modest relative to Aurobindo's overall scale, it is margin-accretive (EBITDA margin ~25.5%) and should be viewed as a strategic, value-additive expansion, likely to be received positively by the market.